UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

Clinical cancer research, 2010-02, Vol.16 (4), p.1191-1205

2010

Volltextzugriff (PDF)

Monoclonal Antibody Cetuximab Binds to and Down-regulates Constitutively Activated Epidermal Growth Factor Receptor vIII on the Cell Surface

Anticancer research, 2007-09, Vol.27 (5A), p.3355-3366

2007

Volltextzugriff (PDF)

Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer

Clinical cancer research, 2006-11, Vol.12 (21), p.6573-6584

2006

Volltextzugriff (PDF)

Tailoring in Vitro Selection for a Picomolar Affinity Human Antibody Directed against Vascular Endothelial Growth Factor Receptor 2 for Enhanced Neutralizing Activity

The Journal of biological chemistry, 2003-10, Vol.278 (44), p.43496-43507

2003

Volltextzugriff (PDF)

Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy

International journal of cancer, 2002-01, Vol.97 (3), p.393-399

2002

Volltextzugriff (PDF)

Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody

The Journal of biological chemistry, 2004-01, Vol.279 (4), p.2856-2865

2004

Volltextzugriff (PDF)

Development of a Fully Human Anti-PDGFRβ Antibody That Suppresses Growth of Human Tumor Xenografts and Enhances Antitumor Activity of an Anti-VEGFR2 Antibody

Neoplasia (New York, N.Y.), 2009-06, Vol.11 (6), p.594-604

2009

Volltextzugriff (PDF)

The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody

Biochemical and biophysical research communications, 2004-05, Vol.318 (2), p.507-513

2004

Volltextzugriff (PDF)

Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target

Molecular cancer therapeutics, 2005-03, Vol.4 (3), p.369-379

2005

Volltextzugriff (PDF)

A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3

Molecular cancer therapeutics, 2005-03, Vol.4 (3), p.427-434

2005

Volltextzugriff (PDF)

Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor

Cancer research (Chicago, Ill.), 2001-10, Vol.61 (19), p.7002-7008

2001

Volltextzugriff (PDF)

Di-diabody: a novel tetravalent bispecific antibody molecule by design

Journal of immunological methods, 2003-08, Vol.279 (1), p.219-232

2003

Volltextzugriff (PDF)

Correction: Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human antihuman VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C

Journal of cell science, 2023-09, Vol.136 (17)

2023

Volltextzugriff (PDF)

Single Variable Domain-IgG Fusion

The Journal of biological chemistry, 2006-04, Vol.281 (16), p.10706-10714

2006

Volltextzugriff (PDF)

A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo

Cancer research (Chicago, Ill.), 2003-12, Vol.63 (24), p.8912-8921

2003

Volltextzugriff (PDF)

Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2

Biochemical and biophysical research communications, 2006-06, Vol.345 (1), p.438-445

2006

Volltextzugriff (PDF)

Single Variable Domain-IgG Fusion: A NOVEL RECOMBINANT APPROACH TO Fc DOMAIN-CONTAINING BISPECIFIC ANTIBODIES

The Journal of biological chemistry, 2006-04, Vol.281 (16), p.10706-10714

2006

Volltextzugriff (PDF)

Entrevista a Josefina Caball

Quaderns (Universitat Autònoma de Barcelona. Departament de Traducció i d'Interpretació), 2020-05, Vol.27, p.187-195

Raya Jiménez, Xènia

2020

Volltextzugriff (PDF)

Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C

Journal of cell science, 2004-06, Vol.117 (Pt 13), p.2745-2756

2004

Volltextzugriff (PDF)

An antibody directed against PDGF receptor β enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody

Biochemical and biophysical research communications, 2007-06, Vol.357 (4), p.1142-1147

2007

Volltextzugriff (PDF)

Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies

Journal of immunological methods, 2007-01, Vol.318 (1), p.65-74

2007

Volltextzugriff (PDF)

Inhibition of Both the Autocrine and the Paracrine Growth of Human Leukemia with a Fully Human Antibody Directed Against Vascular Endothelial Growth Factor Receptor 2

Leukemia & lymphoma, 2004-09, Vol.45 (9), p.1887-1897

2004

Volltextzugriff (PDF)

Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments

Journal of immunological methods, 2002-09, Vol.267 (2), p.213-226

2002

Volltextzugriff (PDF)

Entrevista a Albert Nolla

Quaderns (Universitat Autònoma de Barcelona. Departament de Traducció i d'Interpretació), 2021-06, Vol.28, p.271-282

Raya Jiménez, Xènia

2021

Volltextzugriff (PDF)

Entrevista a Albert Nolla

Quaderns (Universitat Autònoma de Barcelona. Departament de Traducció i d'Interpretació), 2021-05, Vol.28, p.271-282

Raya Jiménez, Xènia

2021

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(49)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

Monoclonal Antibody Cetuximab Binds to and Down-regulates Constitutively Activated Epidermal Growth Factor Receptor vIII on the Cell Surface

Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer

Tailoring in Vitro Selection for a Picomolar Affinity Human Antibody Directed against Vascular Endothelial Growth Factor Receptor 2 for Enhanced Neutralizing Activity

Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy

Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody

Development of a Fully Human Anti-PDGFRβ Antibody That Suppresses Growth of Human Tumor Xenografts and Enhances Antitumor Activity of an Anti-VEGFR2 Antibody

The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody

Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target

A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3

Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor

Di-diabody: a novel tetravalent bispecific antibody molecule by design

Correction: Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human antihuman VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C

Single Variable Domain-IgG Fusion

A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo

Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2

Single Variable Domain-IgG Fusion: A NOVEL RECOMBINANT APPROACH TO Fc DOMAIN-CONTAINING BISPECIFIC ANTIBODIES

Entrevista a Josefina Caball

Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C

An antibody directed against PDGF receptor β enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody

Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies

Inhibition of Both the Autocrine and the Paracrine Growth of Human Leukemia with a Fully Human Antibody Directed Against Vascular Endothelial Growth Factor Receptor 2

Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments

Entrevista a Albert Nolla

Entrevista a Albert Nolla

Suchergebnisse filtern